- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01047111
Esophagectomy: Sweet Versus Ivor-Lewis (ESVIL) (ECTOP-2001) (ESVIL)
A Phase Ⅲ Study of Left Side Thoracotomy Approach (Sweet Procedure) Versus Right Side Thoracotomy Plus Midline Laparotomy Approach (Ivor-Lewis Procedure) Esophagectomy in Middle or Lower Third Intrathoracic Esophageal Cancer
Study Overview
Detailed Description
Background :
Esophageal carcinoma is an aggressive disease with a poor prognosis. Surgical resection remains the basic method of management of this malignancy. Although different approaches have been described for the surgical resection of esophageal cancer, there is no statistical evidence based on large scale prospective randomized trials with regard to the issue that which is the optimal surgical approach for esophageal cancer. In middle or lower third intrathoracic esophageal cancer, a great number of thoracic surgeon preferred the Ivor-Lewis Procedure(Right Side Thoracotomy plus Midline Laparotomy Approach), and believe that this approach can get better exposure for the upper mediastinal node dissection so can get the better long-term survival. But some others preferred the Sweet Procedure(Left Side Thoracotomy Approach),especially in china, more than two of the third unit performed the left side approach esophagectomy routinely and the long-term survival was reported equal to even better than the right side approach. The purpose of this study is to conduct a large scale prospective randomized Phase Ⅲ clinical trial to test that based on the long-term outcomes(overall survival and disease free survival )and postoperative short-term outcomes(mortality, morbidity),whether one approach is superior than the other approach or not.
Objectives:
- To compare overall survival after right side approach and left side approach esophagectomy
- To compare locoregional recurrence, disease free survival after right side approach and left side approach esophagectomy
- To compare postoperative morbidity and mortality in the two groups
- To evaluate short and long term quality of life after the two procedures
Design: Prospective randomized controlled
Setting: Fudan University Cancer Center, Shanghai, China.
Patients and methods : All patients with biopsy proven carcinoma of the middle or lower third of the esophagus presenting to our hospital will be considered for the study.
Staging investigations will be standard and will include
- Computed Tomography (CT) scans in all patients
- Esophagogastroscopy
- Barium swallow
- Endoscopic Ultrasonography (EUS) wherever possible
- PET-CT scan wherever possible
Randomization:
Block randomization will be done using a computer generated sheet. Randomization will be performed 3 days to 1 week before the operation.
All surgeries will be performed under general anesthesia with epidural analgesia. The surgery will be either performed by or under the direct supervision of consultant thoracic surgeons with experience in esophageal surgery. Operative time, blood loss, blood product replacement and all intraoperative details will be recorded in the proforma. Patients will be shifted postoperatively to the intensive care unit (ICU) for observation and subsequently to the recovery or high dependency ward once stabilized. Postoperative details including period of postoperative ventilation, hemorrhage, pulmonary and cardiac complications, arrhythmias, thoracic duct leak, anastomotic leak, wound infection and recurrent laryngeal nerve paresis or palsy will be recorded. Postoperative mortality will be defined as 30-day mortality plus death before discharge after surgery. The total duration of ICU stay and hospital stay will also be recorded.
Follow up:
Patients will be followed up three monthly for the first two years and six monthly for the third to fifth years and annually thereafter. A detailed history and clinical examination and CT scan, barium swallow and ultrasound will be done routinely on every follow up.
Data management: All collected data will be entered into a statistical software package for subsequent analysis
Main research variables:
Primary end point: Disease free survival in the two arms
Secondary endpoints:
- Overall survival
- Locoregional recurrence
- Postoperative morbidity and mortality
- Quality of life : assessed with EORTC QLQ-C30 scale and EORTC QLQ- OES18 scale.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Fudan University Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with histologically proven squamous cell esophageal cancer
- Patients with cT1-T3/N0-N1 mid or distal third (inferior to carina and 3cm superior to cardia ) operable esophageal lesion. Staging investigations including esophagogastroscopy, chest and abdominal CT scan, barium swallow and selective endoscopic ultrasonography showing no evidence of invading adjacent structure such as spine, bronchus, pericardium , descending aorta and without enlargement cervical and celiac nodes (diameter of short axis greater than 1.5cm) measured at CT scans.
- Karnofsky performance status greater than or equal to 80%
- Pulmonary and cardiac function must be acceptable for surgery according to institutional standards.
- Acceptable hepatic, renal and bone marrow function
Exclusion Criteria:
- Patients with low performance status(Karnofsky score <80%)
- Past history of malignancy
- Stage investigations indicating unresectable advanced disease(T4 or M1a,M1b)
- Patients with any other serious underlying medical condition that would impair the ability of the patient to receive or comply with protocol treatment
- Patients medically unfit for surgical resection
- Patients with pulmonary reserve inadequate to undergo thoracotomy and extensive mediastinal lymphadenectomy.
- Patients with a significant history of unstable cardiovascular disease that in the opinion of the treating physician should preclude the patient from protocol treatment.
- Uncontrolled diabetes mellitus or uncontrolled infection, including HIV or interstitial pneumonia or interstitial fibrosis.
- Significant psychiatric illness that would interfere with patient compliance
- Patients with severe hepatic cirrhosis or with serious renal disease unacceptable for surgery
- Patients considered of salvage surgery after definitive chemoradiotherapy
- Patients after neoadjuvant chemoradiotherapy
- Patients above the age of 75 years
- Patients unreliable for follow up
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Ivor-Lewis Procedure
Arm A: Esophagectomy was conducted through right side thoracotomy plus midline laparotomy approach:Ivor-Lewis Procedure.
|
Esophagectomy Through Right Side Thoracotomy plus Midline Laparotomy Approach: Ivor-Lewis Procedure VS Esophagectomy Through Left Side Thoracotomy Approach: Sweet Procedure
Other Names:
|
|
Active Comparator: Sweet Procedure
Arm B: Esophagectomy was conducted through left side thoracotomy or thoracoabdominal incision: Sweet Procedure
|
Esophagectomy Through Right Side Thoracotomy plus Midline Laparotomy Approach: Ivor-Lewis Procedure VS Esophagectomy Through Left Side Thoracotomy Approach: Sweet Procedure
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Disease free survival
Time Frame: 6 years
|
6 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall survival
Time Frame: 6 years
|
6 years
|
|
postoperative morbidity and mortality
Time Frame: 3 years
|
3 years
|
|
Locoreginal recurrence and recurrence pattern
Time Frame: 6 years
|
6 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Haiquan Chen, MD, Fudan University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201001ECFD
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Neoplasms
-
Sun Yat-sen UniversityCompletedEsophageal Adenocarcinoma | Esophageal Carcinoma | Esophagectomy | PaO2 | Esophageal Anastomotic LeakeageChina
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal Adenocarcinoma | Stage IIB Esophageal Adenocarcinoma | Stage IB Esophageal Adenocarcinoma | Stage IIA Esophageal AdenocarcinomaUnited States
-
University Hospital, LilleFederation of Research in Surgery (FRENCH); French Eso-Gastric Tumors Working... and other collaboratorsCompleted
-
Universitaire Ziekenhuizen KU LeuvenCompletedEsophageal Carcinoma (Squamous Cell Carcinoma - Adenocarcinoma)Belgium
-
Emory UniversityNovartisCompletedEsophageal Cancer | Neoplasms, EsophagealUnited States
-
Institute of Oncology LjubljanaCompletedEsophageal Cancer | Esophageal CarcinomaSlovenia
-
Peking UniversityNot yet recruiting
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnStage IIB Esophageal Cancer AJCC v7 | Stage III Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7
-
CellSeed Inc.Terminated
-
University of Michigan Rogel Cancer CenterGenentech, Inc.TerminatedLoco-regional Esophageal Cancer
Clinical Trials on Esophagectomy
-
GEM Hospital & Research CenterUnknown
-
Austrian Society Of Surgical OncologyCompletedEsophageal Cancer
-
University of California, IrvineWithdrawn
-
Sichuan UniversityUnknownPostoperative Complications | Esophageal Cancer | Pulmonary Function | DiaphragmChina
-
Shanghai Chest HospitalChanghai Hospital; The First Affiliated Hospital of Nanchang University; Shanghai... and other collaboratorsRecruitingEsophageal Cancer | Esophageal CarcinomaChina
-
University Hospital, LilleNot yet recruitingResecable Esophageal or Gastroesophageal Junction CancerFrance
-
Cancer Institute and Hospital, Chinese Academy...Zhejiang Cancer Hospital; Sun Yat-sen University; Shanghai Zhongshan Hospital; Fujian... and other collaboratorsUnknown
-
University of BolognaCompletedAdenocarcinoma of the Esophagus | Adenocarcinoma of the Gastric CardiaItaly
-
Shanghai Zhongshan HospitalCompletedLymph Node MetastasisChina
-
Weill Medical College of Cornell UniversityTerminatedEsophageal NeoplasmsUnited States